eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
7/2007
vol. 11
 
Share:
Share:
abstract:

Docetaxel and anthracycline in neoadjuvant treatment of breast cancer. Efficacy evaluation according to molecular factors

Katarzyna Szydłowska-Pazera
,
Piotr Potemski
,
Robert Kubiak
,
Anna Płużańska

Współczesna Onkologia (2007) vol. 11; 7 (360–366)
Online publish date: 2007/10/02
View full text Get citation
 
Background: Molecular markers of proliferation (Ki-67 antigen) and apoptosis (P53 and Bcl-2 protein) are among the most extensively examined prognostic and predictive factors of neoadjuvant chemotherapy with taxoid and anthracycline. Aim: The assessment of molecular factors associated with clinical response and prognosis. Patients and methods: The study was conducted on a group of 50 women aged 37-81 with locally advanced, primary inoperable breast cancer. All patients were treated in the Regional Oncology Center in £ódź between April 2001 and December 2004. They received two-drug combination of docetaxel at a dose of 75 mg/m2 and anthracycline (doxorubicin 50 mg/m2 or mitoxantrone 12 mg/m2). The clinical response was assessed according to RECIST criteria. For all patients, primary paraffin-embedded tumor specimens were available. Immunostaining for Ki-67 antigen, P53 protein, and Bcl-2 protein was done in the Pathology Department, Chair of Oncology, Medical University of £ódź. Results: Objective response was observed in 84% of patients; CR (complete response) in 4%, PR (partial response) in 80%. SD (stable disease) classified as no response was seen in 16% of patients. No PD (disease progression) was observed. High expression of Ki-67 antigen after chemotherapy was associated with the worse efficacy of the treatment. The relative risk of recurrence was lower by 73% when Bcl-2 protein was found in tumor cells. High expression of Ki-67 and P53 positivity were associated with an increase of the relative risk of recurrence over three-fold. Patients with tumors positive for P53 protein were at three-fold higher risk of cancer-related death. Conclusions: In patients with locally advanced breast cancer, combination of docetaxel and anthracycline almost always leads to the achievement of tumor remission and allows definitive surgery. Ki-67 expression is associated with clinical response. Ki-67, P53 and Bcl-2 expression are prognostic factors.
keywords:

breast cancer, neoadjuvant chemotherapy, molecular factors

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.